Atossa Therapeutics Strengthens Patent Protection for Z-Endoxifen with Recent Developments in Israel
Atossa's Recent Patent Developments
Atossa Therapeutics is excited to announce important advancements in its global patent strategy regarding Z-endoxifen, a promising therapeutic agent in breast cancer treatment and prevention. The company, based in Seattle and publicly traded on Nasdaq under the symbol ATOS, has secured a new patent in Israel, identified as No. 304863, which includes groundbreaking formulations and manufacturing methodologies critical to their ongoing clinical programs.
This recent patent issuance highlights Atossa's commitment to protecting its innovative research and represents a key step in their strategy to ensure both product quality and security of intellectual property across various jurisdictions. The Israeli patent, granted on July 2, 2025, pertains to the
Topics Other）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.